SCHEMBL22472894

SCHEMBL22472894

COC(=O)N1C(C)CC(N2CCC3(CC2)CNC(=O)O3)CC1C

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.36
CHRM2 P08172 1/20 0.36
ADRA2A P08913 1/20 0.36
CYP2D6 P10635 1/20 0.36
TSHR P16473 1/20 0.36
DRD1 P21728 1/20 0.36
MAPT P10636 1/20 0.36
KMT2A Q03164 1/20 0.36
HDAC1 Q13547 7/20 0.35
PDCD1LG2 Q9BQ51 1/20 0.33
CD274 Q9NZQ7 1/20 0.33
KCNH2 Q12809 3/20 0.32
JAK2 O60674 1/20 0.31
JAK1 P23458 1/20 0.31
ATR Q13535 1/20 0.31
ATRIP Q8WXE1 1/20 0.31
CDK8 P49336 1/20 0.30
CDK19 Q9BWU1 1/20 0.30
SMO Q99835 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22472866 0.90 LMNA (0.36) LMNACHRM2ADRA2ACYP2D6TSHR
SCHEMBL22449325 0.87 LMNA (0.36) LMNACHRM2ADRA2ACYP2D6TSHR
SCHEMBL20942027 0.81 LMNA (0.34) LMNACHRM2ADRA2ACYP2D6TSHR
SCHEMBL17101358 0.78 CHRM1 (0.42) LMNACHRM2ADRA2ACYP2D6TSHR
SCHEMBL22472919 0.78 OPRK1 (0.30)
SCHEMBL22472925 0.78 CYP11B1 (0.34) CYP2D6PDCD1LG2CD274JAK2JAK1
SCHEMBL21597936 0.77 CHRM1 (0.35) LMNACHRM2ADRA2ACYP2D6TSHR
SCHEMBL18075929 0.76 CHRM4 (0.42) LMNACHRM2ADRA2ACYP2D6TSHR
SCHEMBL17101373 0.76 CHRM1 (0.40) LMNACHRM2ADRA2ACYP2D6TSHR
SCHEMBL23289891 0.76 LMNA (0.41) LMNACHRM2ADRA2ACYP2D6TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10787447-B2 Pharmaceutical compounds HEPTARES THERAPEUTICS LIMITED (GB) 2020-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10787447-B2 Pharmaceutical compounds CHRM1, CHRM2, CHRM4 LMNA 3439/4885CHRM2 2/4885ADRA2A 25/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.